Global Gynecological Cancers Therapeutics Market is segmented By Cancer Type(Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer, Cervical Cancer), By Therapy(Targeted Therapy, Avastin, Lynparza, Zejula, Rubraca, Vitrakvi, Tivdak, Votrient), Chemotherapy((Dacarbazine (DTIC), Gemcitabine (Gemzar), Epirubicin (Ellence), Paclitaxel (Taxol), Platinol, Paraplatin, Immunotherapy, Keytruda, Hormonal Therapy, Goserelin (Zoladex), Leuprolide (Lupron), Megestrol (Megace), Tamoxifen, Anastrozole (Arimidex)), By End-user( Hospitals, Cancer Centers, Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,2024-2031
Market Overview
The global "gynecological cancers therapeutics market" size is estimated to reach at a high CAGR during the forecast period 2024-2031
Cancer refers to a specific group of disorders, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs, such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.
Market Dynamics
The global gynecological cancers therapeutics market growth is driven by the high incidence of gynecological cancers, rise in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer and increase in risk factors that lead to cancer drive the market growth.
A growing robust pipeline of novel drugs is expected to drive the growth in the forecast period
The presence of a robust pipeline, new drug approvals, and the availability of advanced diagnostic modalities are anticipated to boost the market's growth.
The pipeline for the treatment of gynecological cancers includes targeted therapy products, gene therapy, and vaccines. Targeted therapy products and vaccines are in the late stages of clinical development, while gene therapy is early. These products are innovative in terms of advanced therapeutic mechanisms of action such as PARP inhibition, cell cycle inhibition, programmed death-ligand 1 (PD-L1) inhibition, and angiogenesis inhibition and are expected to change the course of gynecological cancer treatment. Furthermore, regulatory agencies such as the US FDA are granting approvals for therapeutics indicated for the treatment of gynecological cancers. For instance, Olaparib, manufactured by AstraZeneca under the brand name LYNPARZA, was approved in December 2018. Thus, a strong pipeline and approval of new drugs are expected to drive market growth during the forecast period.
Furthermore, the availability of advanced diagnostic modalities ensures an appropriate diagnosis of the disease by identifying targets for therapies. With the possibility of the early detection of gynecological cancer, the demand for diagnostic tools such as DNA microarray, complementary DNA fingerprinting, molecular profiling, and polymerase chain reaction to diagnose cancer in its early stage is increasing. This will drive the gynecological cancers therapeutics market to grow at the highest CAGR during the forecast period.
The high cost of treatment and threat of failure & adverse effects of cancer drug therapy is likely to hamper the market growth
The direct costs associated with the initial screening, diagnostic procedures, counselling, outpatient visits, surgery, inpatient charges, palliative care, and emergency services and the indirect fees, including absence from work and premature death, had contributed to the overall high cost of treatment. Additionally, adverse effects of cancer drug therapy like neutropenia, lymphedema, alopecia, nausea, deep vein thrombosis etc are likely to restrain the market growth.
Industry Analysis
Supply Chain Analysis
Opportunities
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.
Segment Analysis
The chemotherapy segment is expected to hold the largest share in this market segment
The chemotherapy segment accounted for the largest market share and is expected to maintain this trend throughout the forecast period. In recent years, combination chemotherapy has been considered a standard treatment mode for cancer treatment due to its effectiveness in an increase in survival & remission rates. For instance, combination therapy of gemcitabine with a platinum compound produced high response rates (as high as 71%) in patients suffering from ovarian cancer. Similarly, gemcitabine is used in combination with other compounds and cytotoxic agents to treat ovarian cancer effectively. Popular varieties include gemcitabine with a platinum compound and paclitaxel and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for the treatment of epithelial ovarian cancer has a combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere).
Geographical Share
North America region holds the largest market share of the global gynecological cancers therapeutics market
North America served the largest share of the market due to the increasing prevalence of cancer cases. The prime reason for the market's growth in this region is the rising incidence of the disease and the growing awareness among the general population. According to the American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, about 10% of uterine body cancers are rare sarcoma. increasing incidences of cervical cancer and growing research and development activities by various healthcare regulatory organizations in this region. For instance, according to the American Cancer Society's (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed, and around 4,170 women are expected to die from cervical cancer. Moreover, the increase in funding by the American Cancer Society, in March 2018, funded approximately 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, including a specific type of cancer or area of cancer.
Competitive Landscape
The global gynecological cancers therapeutics market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, GlaxoSmithKline plc, Merck & Co., Inc, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Apotex Inc and Eli Lilly and Company.
Global Gynecological Cancers Therapeutics Market – Key Companies to Watch
F. Hoffmann-La Roche Ltd
Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Product Portfolio: The company portfolio includes Bevacizumab (Avastin) belongs to a class of drugs called angiogenesis inhibitors. The company offers AVASTIN, which is indicated in combination with carboplatin and paclitaxel.
